<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom"  xmlns:media="http://search.yahoo.com/mrss/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:georss="http://www.georss.org/georss" xmlns:photo="http://www.pheed.com/pheed/">
 <title>Daily CSR</title>
 <subtitle><![CDATA[Daily CSR delivers latest news and in-depth coverage about corporate social responsibility, ethics and sustainability]]></subtitle>
 <link rel="alternate" type="text/html" href="https://www.dailycsr.com" />
 <link rel="self" type="text/xml" href="https://www.dailycsr.com/xml/atom.xml" />
 <id>https://www.dailycsr.com/</id>
 <updated>2026-05-11T07:28:29+02:00</updated>
 <generator uri="http://www.wmaker.net">Webzine Maker</generator>
  <icon>https://www.dailycsr.com/favicon.ico</icon>
  <entry>
   <title>NuScale Power (SMR) Class Action Lawsuit: Lead Plaintiff Deadline April 20, 2026</title>
   <updated>2026-02-28T13:06:00+01:00</updated>
   <id>https://www.dailycsr.com/NuScale-Power-SMR-Class-Action-Lawsuit-Lead-Plaintiff-Deadline-April-20-2026_a5582.html</id>
   <category term="Companies" />
   <photo:imgsrc>https://www.dailycsr.com/photo/art/imagette/94990853-66560589.jpg</photo:imgsrc>
   <published>2026-02-28T13:03:00+01:00</published>
   <author><name>Debashish Mukherjee</name></author>
   <content type="html">
    <![CDATA[
     <div style="position:relative; text-align : center; padding-bottom: 1em;">
      <img src="https://www.dailycsr.com/photo/art/default/94990853-66560589.jpg?v=1772280359" alt="NuScale Power (SMR) Class Action Lawsuit: Lead Plaintiff Deadline April 20, 2026" title="NuScale Power (SMR) Class Action Lawsuit: Lead Plaintiff Deadline April 20, 2026" />
     </div>
     <div>
      <div style="text-align: justify;">Robbins Geller Rudman &amp; Dowd LLP has announced that investors who bought NuScale Power Corporation (NYSE: SMR) Class A common stock between May 13, 2025 and November 6, 2025 (the “Class Period”) have until April 20, 2026 to apply for appointment as lead plaintiff in a securities class action. The case, titled <em>Truedson v. NuScale Power Corporation</em>, No. 26-cv-00328 (D. Or.), alleges violations of the Securities Exchange Act of 1934 against NuScale, certain senior executives, and Fluor Corporation. <br />   <br />  Investors who experienced significant losses and wish to pursue the role of lead plaintiff may submit their information through the firm’s website or contact attorney J.C. Sanchez at 800-449-4900 or via email at <a class="link" href="javascript:protected_mail('info@rgrdlaw.com')" >info@rgrdlaw.com</a>  .</div>    <h3 style="text-align: justify;">Allegations in the Case</h3>    <div style="text-align: justify;">NuScale’s primary technology, the NuScale Power Module (NPM), is a small modular nuclear reactor intended for use in larger energy facilities. Before the Class Period began, NuScale formed a worldwide commercialization partnership with ENTRA1 Energy LLC, presenting the alliance as a key step toward moving its NPM technology from development to commercial deployment. Confidence in this strategy appeared to grow when, on September 2, 2025, ENTRA1 and the Tennessee Valley Authority announced an agreement to develop facilities capable of delivering up to six gigawatts of nuclear power. <br />   <br />  The lawsuit, however, contends that throughout the Class Period, defendants made misleading statements or omitted material information. Specifically, the complaint alleges that:</div>    <ol>  	<li style="text-align: justify;">ENTRA1 had no track record of building, financing, or operating major projects, particularly in the highly specialized nuclear energy sector.</li>  	<li style="text-align: justify;">NuScale committed substantial capital and entrusted commercialization, distribution, and deployment of its NPM technology to a partner lacking meaningful experience in nuclear facility ownership or operations.</li>  	<li style="text-align: justify;">The qualifications cited by defendants largely related to individuals associated with the Habboush Group—an entity separate from ENTRA1 and without notable nuclear energy expertise.</li>  	<li style="text-align: justify;">These factors exposed NuScale’s commercialization strategy to significant, undisclosed risks, including potential delays, regulatory hurdles, and project failures.</li>  </ol>    <div style="text-align: justify;">The complaint further alleges that on November 6, 2025, NuScale disclosed that its general and administrative expenses had surged to $519 million in the third fiscal quarter, compared to $17 million during the same period the prior year. The increase was reportedly driven in large part by a $495 million payment to ENTRA1 connected to the TVA agreement. Consequently, NuScale’s quarterly net loss expanded to $532 million, up from $46 million year-over-year. <br />   <br />  During the related earnings call, analysts questioned whether ENTRA1 possessed adequate experience to manage and operate the nuclear facilities outlined in the TVA arrangement. NuScale’s CEO, John L. Hopkins, also stated that the agreement contemplated up to 72 NPM units, suggesting milestone payments to ENTRA1 could exceed $3 billion. Following these disclosures, NuScale’s Class A share price fell more than 12% over two trading days.</div>    <h3 style="text-align: justify;">Lead Plaintiff Information</h3>    <div style="text-align: justify;">Under the Private Securities Litigation Reform Act of 1995, investors who purchased NuScale Class A common stock during the Class Period may petition the court to serve as lead plaintiff. Typically, the court appoints the investor with the largest financial stake who also satisfies requirements of adequacy and typicality. The lead plaintiff represents the interests of all class members and selects legal counsel for the case. Importantly, participation in any future recovery does not depend on serving as lead plaintiff.</div>  
     </div>
     <br style="clear:both;"/>
    ]]>
   </content>
   <link rel="alternate" href="https://www.dailycsr.com/NuScale-Power-SMR-Class-Action-Lawsuit-Lead-Plaintiff-Deadline-April-20-2026_a5582.html" />
  </entry>
  <entry>
   <title>Tandem Diabetes Care (TNDM) Investors: Class Action Lawsuit &amp; Stock Drop Recovery</title>
   <updated>2026-01-22T03:48:00+01:00</updated>
   <id>https://www.dailycsr.com/Tandem-Diabetes-Care-TNDM-Investors-Class-Action-Lawsuit-Stock-Drop-Recovery_a5476.html</id>
   <category term="Companies" />
   <photo:imgsrc>https://www.dailycsr.com/photo/art/imagette/93824906-65508721.jpg</photo:imgsrc>
   <published>2026-01-22T03:46:00+01:00</published>
   <author><name>Debashish Mukherjee</name></author>
   <content type="html">
    <![CDATA[
     <div style="position:relative; text-align : center; padding-bottom: 1em;">
      <img src="https://www.dailycsr.com/photo/art/default/93824906-65508721.jpg?v=1769050077" alt="Tandem Diabetes Care (TNDM) Investors: Class Action Lawsuit &amp; Stock Drop Recovery" title="Tandem Diabetes Care (TNDM) Investors: Class Action Lawsuit &amp; Stock Drop Recovery" />
     </div>
     <div>
      <p style="text-align:justify;text-justify:inter-ideograph"><strong>Why This Matters:</strong> Rosen Law Firm, a global firm specializing in investor rights, is reviewing possible securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM). These claims stem from allegations that the company may have provided materially misleading information about its business operations to investors.<o:p></o:p> <br />    <p style="text-align:justify;text-justify:inter-ideograph"><strong>Potential Impact for Investors:</strong> If you purchased securities of Tandem Diabetes, you might qualify for compensation through a contingency fee arrangement, meaning you wouldn’t pay any upfront fees. Rosen Law Firm is preparing a class action lawsuit aimed at recovering losses for affected investors.<o:p></o:p> <br />    <p style="text-align:justify;text-justify:inter-ideograph"><strong>Next Steps:</strong> To become part of the potential class action, visit <a class="link" href="https://rosenlegal.com/submit-form/?case_id=19024">https://rosenlegal.com/submit-form/?case_id=19024</a>, call Phillip Kim, Esq. toll-free at 866-767-3653, or email <strong><a class="link" href="javascript:protected_mail('case@rosenlegal.com')" >case@rosenlegal.com</a>  </strong> for more information.<o:p></o:p> <br />    <p style="text-align:justify;text-justify:inter-ideograph"><strong>Background:</strong> On August 7, 2025, before markets opened, Tandem Diabetes Care issued a press release titled <em>“Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps.”</em> The statement noted a voluntary correction for certain t:slim X2 insulin pumps to resolve a potential speaker-related issue that could disrupt insulin delivery. Following this announcement, Tandem Diabetes’ stock price dropped nearly 20% on the same day.<o:p></o:p> <br />    <p style="text-align:justify;text-justify:inter-ideograph"><strong>Why Choose Rosen Law Firm:</strong> Selecting experienced counsel with a proven track record is critical. Many firms sending notices lack the expertise, resources, or recognition in securities litigation. Rosen Law Firm focuses exclusively on securities class actions and shareholder derivative cases. The firm achieved the largest securities class action settlement ever against a Chinese company, has been ranked among the top four firms for settlements since 2013, and recovered hundreds of millions for investors—including $438 million in 2019 alone. Founder Laurence Rosen was named a Titan of the Plaintiffs’ Bar by Law360 in 2020, and multiple attorneys at the firm have been recognized by Lawdragon and Super Lawyers.<o:p></o:p> <br />    <p style="text-align:justify;text-justify:inter-ideograph"><strong>Stay Updated:</strong> Follow Rosen Law Firm on <a class="link" href="https://www.linkedin.com/company/the-rosen-law-firm">LinkedIn</a>, <a class="link" href="https://twitter.com/rosen_firm">Twitter</a>, or <a class="link" href="https://www.facebook.com/rosenlawfirm/">Facebook</a>.<o:p></o:p> <br />    <p style="text-align:justify;text-justify:inter-ideograph"><strong>Attorney Advertising:</strong> Past results do not guarantee similar outcomes.<o:p></o:p> <br />    <p style="text-align:justify;text-justify:inter-ideograph"><strong>Contact Information:</strong> <br />  Laurence Rosen, Esq. <br />  Phillip Kim, Esq. <br />  The Rosen Law Firm, P.A. <br />  275 Madison Avenue, 40th Floor <br />  New York, NY 10016 <br />  Tel: (212) 686-1060 | Toll-Free: (866) 767-3653 <br />  Fax: (212) 202-3827 <br />  Email: <strong><a class="link" href="javascript:protected_mail('case@rosenlegal.com')" >case@rosenlegal.com</a>  </strong> <br />  Website: <a class="link" href="http://www.rosenlegal.com/">www.rosenlegal.com</a>  <o:p></o:p> <br />  
     </div>
     <br style="clear:both;"/>
    ]]>
   </content>
   <link rel="alternate" href="https://www.dailycsr.com/Tandem-Diabetes-Care-TNDM-Investors-Class-Action-Lawsuit-Stock-Drop-Recovery_a5476.html" />
  </entry>
</feed>
